Sotatercept in patients with osteolytic lesions of multiple myeloma

This phase IIa study evaluated the safety and tolerability of sotatercept, and its effects on bone metabolism and haematopoiesis in newly diagnosed and relapsed multiple myeloma (MM) patients. Patients were randomized (4:1) to receive four 28-d cycles of sotatercept (0·1, 0·3, or 0·5 mg/kg) or place...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdulkadyrov, Kudrat M, Salogub, Galina N, Khuazheva, Nuriet K, Sherman, Matthew L, Laadem, Abderrahmane, Barger, Rachel, Knight, Robert, Srinivasan, Shankar, Terpos, Evangelos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2014
Materias:
Haematological Malignancy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4312883/
https://www.ncbi.nlm.nih.gov/pubmed/24650009
http://dx.doi.org/10.1111/bjh.12835

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4312883/
https://www.ncbi.nlm.nih.gov/pubmed/24650009
http://dx.doi.org/10.1111/bjh.12835

Ejemplares similares